Outlook Therapeutics Inc
NASDAQ:OTLK 4:00:00 PM EDT
| Market Cap (Intraday) | 68.57M |
| Current PE | 3.25 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.69 |
| 50-Day MA | $1.68 |
| 200-Day MA | $2.75 |
Outlook Therapeutics Inc Stock, NASDAQ:OTLK
111 South Wood Avenue, Unit 100, Iselin, New Jersey 08830
United States of America
Phone: +1.609.619.3990
Number of Employees: 23
Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.